Compare VERU & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERU | AIRE |
|---|---|---|
| Founded | 1971 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9M | 39.9M |
| IPO Year | 1996 | 2023 |
| Metric | VERU | AIRE |
|---|---|---|
| Price | $2.25 | $2.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $22.50 | $1.30 |
| AVG Volume (30 Days) | 46.1K | ★ 1.3M |
| Earning Date | 05-12-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.34 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,296,958.00 | $4,518,498.00 |
| Revenue This Year | N/A | $129.06 |
| Revenue Next Year | N/A | $83.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 376.42 |
| 52 Week Low | $0.36 | $0.14 |
| 52 Week High | $4.59 | $3.98 |
| Indicator | VERU | AIRE |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 63.64 |
| Support Level | $2.13 | $0.35 |
| Resistance Level | $2.70 | $3.98 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 21.74 | 54.34 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are Homebuying Services and the Technology Services segment.